We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Interest Income Support E*TRADE's (ETFC) Earnings in Q3?
Read MoreHide Full Article
E*TRADE Financial Corporation is scheduled to report third-quarter 2018 results on Oct 18. The company is expected to witness year-over-year growth in revenues and earnings.
In the last reported quarter, E*TRADE pulled off a positive earnings surprise of 6.7% supported by increased net revenues and benefit from provisions. Further, the quarter witnessed an increase in daily average revenue trades (DARTs) along with growth in customer accounts. However, the positives were partially offset by higher expenses.
Further, E*TRADE has an impressive earnings surprise history. It delivered positive earnings surprises in each of the trailing four quarters with an average beat of 7.3%.
E*TRADE Financial Corporation Price and EPS Surprise
Estimates for the to-be-reported quarter have remained stable at 83 cents over the last seven days. Notably, the Zacks Consensus Estimate for earnings reflects growth of 50.9% year over year.
Factors That Might Influence Q3 Results
Trading Revenues Might Improve: Though market volatility during the third quarter remained subdued compared with first-half 2018, E*TRADE’s trading revenues might have witnessed improvement on the back of rise in net new brokerage accounts. The Zacks Consensus Estimate for these accounts is 45,000, up 71.6% year over year.
Further, as the company reported annual increase in DARTs for the months of July and September, commission revenues are likely to have increased during the quarter. The consensus estimate for DARTs is 266,000, up 29.2% year over year.
Interest Income Might Trend Upward: As net interest income constitutes a significant part of E*TRADE’s revenues, expanding net interest margin (NIM) on the back of rising interest rates will likely lend support this quarter as well. The consensus estimate for NIM indicates a year-over-year rise of 22 basis points to 3.07%.
Also, some support to interest income will be provided by rise in average interest earning assets. The Zacks Consensus Estimate of $61.2 billion reflects a year-over-year increase of 9.8%.
Notably, the consensus estimate for sales is $715.2 million, indicating improvement of 19.4% from the year-ago quarter.
Expenses Might Trend Up: The company plans to make several investments in 2018 along with spending money on marketing. This might lead to an increase in expenses during the quarter.
Earnings Whispers
According to our quantitative model, E*TRADE doesn’t have the right combination of the two key ingredients — positive Earnings ESP and a Zacks Rank #3 (Hold) or better — to increase the odds of an earnings beat.
(You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.)
Earnings ESP: The Earnings ESP for E*TRADE is 0.00%.
Zacks Rank: The stock currently carries a Zacks Rank #2 (Buy).
Stocks That Warrant a Look
Here are some stocks worth considering, as they have the right combination of elements to post an earnings beat this quarter.
T. Rowe Price Group, Inc. (TROW - Free Report) is scheduled to release results on Oct 25. It has an Earnings ESP of +0.78% and carries a Zacks Rank of 2.
Invesco Ltd. (IVZ - Free Report) has an Earnings ESP of +0.38% and carries a Zacks Rank of 3. The company is slated to release results on Oct 24.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Can Interest Income Support E*TRADE's (ETFC) Earnings in Q3?
E*TRADE Financial Corporation is scheduled to report third-quarter 2018 results on Oct 18. The company is expected to witness year-over-year growth in revenues and earnings.
In the last reported quarter, E*TRADE pulled off a positive earnings surprise of 6.7% supported by increased net revenues and benefit from provisions. Further, the quarter witnessed an increase in daily average revenue trades (DARTs) along with growth in customer accounts. However, the positives were partially offset by higher expenses.
Further, E*TRADE has an impressive earnings surprise history. It delivered positive earnings surprises in each of the trailing four quarters with an average beat of 7.3%.
E*TRADE Financial Corporation Price and EPS Surprise
E*TRADE Financial Corporation Price and EPS Surprise | E*TRADE Financial Corporation Quote
Estimates for the to-be-reported quarter have remained stable at 83 cents over the last seven days. Notably, the Zacks Consensus Estimate for earnings reflects growth of 50.9% year over year.
Factors That Might Influence Q3 Results
Trading Revenues Might Improve: Though market volatility during the third quarter remained subdued compared with first-half 2018, E*TRADE’s trading revenues might have witnessed improvement on the back of rise in net new brokerage accounts. The Zacks Consensus Estimate for these accounts is 45,000, up 71.6% year over year.
Further, as the company reported annual increase in DARTs for the months of July and September, commission revenues are likely to have increased during the quarter. The consensus estimate for DARTs is 266,000, up 29.2% year over year.
Interest Income Might Trend Upward: As net interest income constitutes a significant part of E*TRADE’s revenues, expanding net interest margin (NIM) on the back of rising interest rates will likely lend support this quarter as well. The consensus estimate for NIM indicates a year-over-year rise of 22 basis points to 3.07%.
Also, some support to interest income will be provided by rise in average interest earning assets. The Zacks Consensus Estimate of $61.2 billion reflects a year-over-year increase of 9.8%.
Notably, the consensus estimate for sales is $715.2 million, indicating improvement of 19.4% from the year-ago quarter.
Expenses Might Trend Up: The company plans to make several investments in 2018 along with spending money on marketing. This might lead to an increase in expenses during the quarter.
Earnings Whispers
According to our quantitative model, E*TRADE doesn’t have the right combination of the two key ingredients — positive Earnings ESP and a Zacks Rank #3 (Hold) or better — to increase the odds of an earnings beat.
(You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.)
Earnings ESP: The Earnings ESP for E*TRADE is 0.00%.
Zacks Rank: The stock currently carries a Zacks Rank #2 (Buy).
Stocks That Warrant a Look
Here are some stocks worth considering, as they have the right combination of elements to post an earnings beat this quarter.
Franklin Resources (BEN - Free Report) is slated to release results on Oct 25. It has an Earnings ESP of +0.68% and carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
T. Rowe Price Group, Inc. (TROW - Free Report) is scheduled to release results on Oct 25. It has an Earnings ESP of +0.78% and carries a Zacks Rank of 2.
Invesco Ltd. (IVZ - Free Report) has an Earnings ESP of +0.38% and carries a Zacks Rank of 3. The company is slated to release results on Oct 24.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>